User profiles for J. Ancochea

Julio Ancochea

Universidad Autónoma de Madrid
Verified email at uam.es
Cited by 20348

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management

…, JH Ryu, JJ Swigris, AU Wells, J Ancochea… - American journal of …, 2011 - atsjournals.org
This document is an international evidence-based guideline on the diagnosis and management
of idiopathic pulmonary fibrosis, and is a collaborative effort of the American Thoracic …

Burden of disease attributable to second-hand smoke exposure: a systematic review

…, D Nguyen, P Starchenko, J Ancochea… - Preventive …, 2019 - Elsevier
Our aim was to provide a systematic review of studies on the burden of disease due to
second-hand smoke (SHS) exposure, reviewing methods, exposure assessment, diseases …

Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review

…, R Blanco, L Cavagna, J Ancochea… - Autoimmunity …, 2021 - Elsevier
Background Interstitial lung disease (ILD) is a serious complication that represents the
second leading cause of death in patients with rheumatoid arthritis (RA). Treatment of RA-ILD …

Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities

…, G Sanchez, V Sobradillo, J Ancochea - Thorax, 2009 - thorax.bmj.com
Aims: This study aimed to determine the prevalence of chronic obstructive pulmonary disease
(COPD) in Spain and identify the level of undiagnosed disease and its impact on health-…

Determinants of underdiagnosis of COPD in national and international surveys

…, M Miravitlles, F García-Rio, K Akbari, J Ancochea… - Chest, 2015 - Elsevier
BACKGROUND COPD ranks within the top three causes of mortality in the global burden of
disease, yet it remains largely underdiagnosed. We assessed the underdiagnosis of COPD …

The impact of COVID-19 on patients with asthma

…, C Del Rio-Bermudez, J Ancochea… - European …, 2021 - Eur Respiratory Soc
Background An association between the severity of coronavirus disease 2019 (COVID-19)
and the presence of certain chronic conditions has been suggested. However, unlike …

IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study

…, C Suárez-Fernández, J Ancochea… - Journal of Allergy and …, 2021 - Elsevier
Background Patients with coronavirus disaese 2019 (COVID-19) can develop a cytokine
release syndrome that eventually leads to acute respiratory distress syndrome requiring …

Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase.

…, D Rigau, JB Soriano, J Ancochea - Archivos de …, 2017 - europepmc.org
The clinical presentation of chronic obstructive pulmonary disease (COPD) varies widely, so
treatment must be tailored according to the level of risk and phenotype. In 2012, the …

Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD

…, JL López-Campos, JB Soriano, J Ancochea - Archivos de …, 2012 - Elsevier
… Julio Ancochea has been paid to give conferences at educational events and/or for scientific
consulting and/or research by Boehringer Ingelheim, Novartis, Takeda-Nycomed, Almirall, …

Prevalence and determinants of COPD in Spain: EPISCAN II

…, BG Cosío, G Sanchez, J Ancochea - Archivos de …, 2021 - Elsevier
Background Two previous national epidemiological studies, IBERPOC in 1997 and EPISCAN
in 2007, determined the COPD burden in Spain. Changes in demographics and exposure …